Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Celldex Therapeutics Inc. (NASDAQ: CLDX) closed the day trading at $33.28 down -0.54% from the previous closing price of $33.46. In other words, the price has decreased by -$0.54 from its previous closing price. On the day, 0.63 million shares were traded. CLDX stock price reached its highest trading level at $33.82 during the session, while it also had its lowest trading level at $32.78.
Ratios:
For a better understanding of CLDX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 29.36 and its Current Ratio is at 29.36. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on June 18, 2024, initiated with a Buy rating and assigned the stock a target price of $58.
On June 11, 2024, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $51.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 14 ’24 when Crowley Elizabeth sold 30,000 shares for $34.87 per share. The transaction valued at 1,045,962 led to the insider holds 9,074 shares of the business.
Martin Samuel Bates sold 17,172 shares of CLDX for $608,315 on Jun 14 ’24. The SVP AND CFO now owns 28,125 shares after completing the transaction at $35.42 per share. On Jun 07 ’24, another insider, Young Diane C., who serves as the SVP, CHIEF MEDICAL OFFICER of the company, sold 45,000 shares for $35.26 each. As a result, the insider received 1,586,844 and left with 2,115 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CLDX now has a Market Capitalization of 2206051328 and an Enterprise Value of 1406119168. For the stock, the TTM Price-to-Sale (P/S) ratio is 265.80 while its Price-to-Book (P/B) ratio in mrq is 2.71. Its current Enterprise Value per Revenue stands at 169.351 whereas that against EBITDA is -8.778.
Stock Price History:
Over the past 52 weeks, CLDX has reached a high of $53.18, while it has fallen to a 52-week low of $22.11. The 50-Day Moving Average of the stock is -8.75%, while the 200-Day Moving Average is calculated to be -10.17%.
Shares Statistics:
Over the past 3-months, CLDX traded about 700.26K shares per day on average, while over the past 10 days, CLDX traded about 610370 shares per day. A total of 66.29M shares are outstanding, with a floating share count of 65.05M. Insiders hold about 1.86% of the company’s shares, while institutions hold 103.99% stake in the company. Shares short for CLDX as of 1722384000 were 8397023 with a Short Ratio of 11.99, compared to 1719532800 on 6986016. Therefore, it implies a Short% of Shares Outstanding of 8397023 and a Short% of Float of 14.649999.
